Evidence map›Paper›PMID 38612904›Full record

ReviewInternational journal of molecular sciences2024

Roles of Integrin in Cardiovascular Diseases: From Basic Research to Clinical Implications.

Shuo Zhang, Qingfang Zhang, Yutong Lu, Jianrui Chen, Jinkai Liu, Zhuohan Li, Zhenzhen Xie

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. From bump to pump: extracellular matrix remodeling, dynamics, and biomechanics in the maternal heart.American journal of physiology. Heart and circulatory physiology · 2026
    Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Environmental Toxicants and Their Disruption of Integrin Signaling in Lipid Rafts.BioEssays : news and reviews in molecular, cellular and developmental biology · 2025
    Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Shuo ZhangCollege of Basic Medical, Nanchang University, Nanchang 330006, China.
Qingfang ZhangCollege of Basic Medical, Nanchang University, Nanchang 330006, China.
Yutong LuCollege of Basic Medical, Nanchang University, Nanchang 330006, China.
Jianrui ChenCollege of Basic Medical, Nanchang University, Nanchang 330006, China.
Jinkai LiuCollege of Basic Medical, Nanchang University, Nanchang 330006, China.
Zhuohan LiCollege of Basic Medical, Nanchang University, Nanchang 330006, China.
Zhenzhen XieCollege of Basic Medical, Nanchang University, Nanchang 330006, China.ORCID 0000-0002-5989-6118
Nanchang University · CN

Funding

National Natural Science Foundation of China 41966006
6 · The paper itself

Abstract

Cardiovascular diseases (CVDs) pose a significant global health threat due to their complex pathogenesis and high incidence, imposing a substantial burden on global healthcare systems. Integrins, a group of heterodimers consisting of α and β subunits that are located on the cell membrane, have emerged as key players in mediating the occurrence and progression of CVDs by regulating the physiological activities of endothelial cells, vascular smooth muscle cells, platelets, fibroblasts, cardiomyocytes, and various immune cells. The crucial role of integrins in the progression of CVDs has valuable implications for targeted therapies. In this context, the development and application of various integrin antibodies and antagonists have been explored for antiplatelet therapy and anti-inflammatory-mediated tissue damage. Additionally, the rise of nanomedicine has enhanced the specificity and bioavailability of precision therapy targeting integrins. Nevertheless, the complexity of the pathogenesis of CVDs presents tremendous challenges for monoclonal targeted treatment. This paper reviews the mechanisms of integrins in the development of atherosclerosis, cardiac fibrosis, hypertension, and arrhythmias, which may pave the way for future innovations in the diagnosis and treatment of CVDs.

Indexed as

Cardiovascular DiseasesHypertensionCell MembraneEndothelial CellsHumansIntegrinsIntegrinscardiac fibroblastscardiomyocytescardiovascular diseasesintegrin antagonists and antibodiesintegrinsnanotherapyplateletsvascular endothelial cellsvascular smooth muscle cells

Identifiers

PMID38612904
PMCPMC11012347
OpenAlexW4394579600

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.